Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activityWyndham H. Wilson, Rod Humerickhouse, Anil Tulpule et al.|The Lancet Oncology|2010Cited by 852
Pharmacokinetics and Pharmacodynamics of Lansoprazole in Children with Gastroesophageal Reflux DiseaseDavid A. Gremse, Linda Book, Harland S. Winter et al.|Journal of Pediatric Gastroenterology and Nutrition|2002Cited by 31
Aberrantly reduced expression of miR-342-5p contributes to CCND1-associated chronic myeloid leukemia progression and imatinib resistanceYi‐Ying Wu, Yi‐Lin Chiu|Cell Death and Disease|2021Cited by 24
Pharmacokinetics and Pharmacodynamics of Lansoprazole in Children 13 to 24 Months Old With Gastroesophageal Reflux DiseaseMelvin B. Heyman, Harland S. Winter, Fouad Amer et al.|Journal of Pediatric Gastroenterology and Nutrition|2007Cited by 9